Eli Lilly (NYSE:LLY) on Saturday announced detailed data from its ACHIEVE-1 Phase 3 trial, which reached the main goal for ...

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...

An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new ...

Patients with obesity can now get Zepbound’s strongest doses for a flat rate through Lilly’s self-pay pharmacy. Eli Lilly ...

With the addition of the 12.5 milligrams and 15 mg doses, all approved doses of Zepbound will be available on the website in ...

Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following ...

A new generation of weight-loss drugs has proven remarkably effective, hugely popular and massively lucrative in the last few ...

Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...

Compounded GLP-1s are still accessible on telehealth sites, despite an agreement with Eli Lilly to cease copycat sales.

An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

(Reuters) -Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is ...